Clinical Trial Update: Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing safety and tolerability of ferric carboxymaltose to iron dextran in treating iron deficiency anemia has completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)
• Iron Dextran (iron dextran)

Snippet

Sponsor: American Regent, Inc. | Conditions: Anemia | Phase 3 | Status: COMPLETED | Results posted: 2013-11-25